Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors
摘要:
A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.
Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors
摘要:
A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.
Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors
作者:Leon Smith、Evgueni L. Piatnitski、Alexander S. Kiselyov、Xiaohu Ouyang、Xiaoling Chen、Sabina Burdzovic-Wizemann、Yongjiang Xu、Ying Wang、Robin L. Rosler、Sheetal N. Patel、Hui-Hsien Chiang、Daniel L. Milligan、John Columbus、Wai C. Wong、Jacqueline F. Doody、Yaron R. Hadari
DOI:10.1016/j.bmcl.2005.12.018
日期:2006.3
A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.